Utility of PET/CT in assessing early treatment response in patients with newly diagnosed multiple myelomaCharalampos Charalampous, Shaji Kumar, Yi L. Hwa et al.|Blood Advances|2022Cited by 26
Defining drug/drug class refractoriness vs lines of therapy in relapsed/refractory multiple myelomaUtkarsh Goel, Shaji Kumar, Charalampos Charalampous et al.|Blood Cancer Journal|2023Cited by 16
Outcomes of patients with primary refractory multiple myeloma in the era of triplet and quadruplet induction therapyCharalampos Charalampous, Shaji Kumar, Utkarsh Goel et al.|Blood Advances|2023Cited by 16
Outcomes of patients with multiple myeloma refractory to standard dose vs low dose lenalidomideUtkarsh Goel, Shaji Kumar, Charalampos Charalampous et al.|Blood Cancer Journal|2024Cited by 6
Impact of the time interval between end of induction and autologous hematopoietic transplantation in newly diagnosed patients with multiple myelomaCharalampos Charalampous, Shaji Kumar, Utkarsh Goel et al.|Bone Marrow Transplantation|2022Cited by 5